Skip to main content
    PeptideAuthority
    DC

    Dr David Chen, PharmD

    Clinical Pharmacy and Regulatory Affairs — Former MHRA Advisory Panel; current independent practice

    Profile last reviewed: 2026-05-20

    Dr Chen brings expertise in UK pharmaceutical regulation, having served on an MHRA advisory panel on peptide classification. He reviews our regulatory content, patient-education guides, and ensures compliance with UK advertising standards.

    Credentials

    • PharmD — Clinical Pharmacy
    • Member of the Royal Pharmaceutical Society (MRPharmS)
    • Former member of an MHRA advisory panel on peptide classification

    Professional registrations

    • General Pharmaceutical Council (GPhC): Registered pharmacist
    • Royal Pharmaceutical Society: Member (MRPharmS)

    GPhC registration is verifiable by name on the GPhC Online Registers. Registration numbers are not republished here, per standard editorial practice on personal-data minimisation.

    Role on the editorial board

    Lead reviewer for UK regulatory content — Human Medicines Regulations 2012 framing, ‘specials’ supply, advertising rules, MHRA enforcement context, and the UK legal hub. Also reviews patient-education content for compliance with UK advertising standards.

    Conflict of interest disclosures

    • No equity in pharmaceutical or peptide companies.
    • No paid consulting with online prescribing services or peptide retailers.
    • Previously served as a panel member for the MHRA on peptide classification guidance; standard public-body disclosures applied.
    • Does not own, operate, or advise any peptide clinic.

    Disclosures are reviewed annually and updated at the date shown above. See the conflict-of-interest policy for the wider framework.

    Sections reviewed

    • All UK Law hub pages (/legal/*)
    • ‘Not for human consumption’ claims explainer
    • MHRA enforcement page
    • Compounded peptides regulatory analysis
    • Patient-education content for CAP / BCAP / HMR 2012 compliance

    Citation policy

    Regulatory claims must trace to UK statute (legislation.gov.uk), MHRA published guidance, NICE technology appraisals, ASA / CAP code, or named case decisions. Where guidance has been superseded, the page either cites the current version or is flagged for editorial review.

    The site-wide methodology is documented in our evidence grading methodology and editorial standards.

    About the editorial board

    Peptide Authority’s editorial board is responsible for the accuracy, evidence-grading, and UK regulatory framing of the content on this site. Read more about how we work in editorial standards and the corrections policy.

    Other reviewers